Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Colorcon
Baxter
Harvard Business School
McKesson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Reslizumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Reslizumab: Patents, clinical trial progress, indications

Reslizumab is an investigational drug.

There have been 18 clinical trials for Reslizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Asthma, Pulmonary Eosinophilia, and Inflammation. The leading clinical trial sponsors are Teva Branded Pharmaceutical Products, R&D Inc., GlaxoSmithKline, and Teva Pharmaceuticals USA.

There are fourteen US patents protecting this investigational drug and two hundred and sixty international patents.

Recent Clinical Trials for Reslizumab
TitleSponsorPhase
Reslizumab in Patients With Severe Asthma Who Failed to Respond to OmalizumabSociedad Española de Neumología y Cirugía TorácicaPhase 2
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaTeva Branded Pharmaceutical Products, R&D Inc.Phase 3
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway InflammationTeva Branded Pharmaceutical Products, R&D Inc.Phase 4

See all Reslizumab clinical trials

Clinical Trial Summary for Reslizumab

Top disease conditions for Reslizumab
Top clinical trial sponsors for Reslizumab

See all Reslizumab clinical trials

US Patents for Reslizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Reslizumab   See Pricing Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders Knopp Biosciences LLC (Pittsburgh, PA)   See Pricing
Reslizumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Reslizumab   See Pricing Compositions and methods for treating chronic urticaria Knopp Biosciences LLC (Pittsburgh, PA)   See Pricing
Reslizumab   See Pricing Soft lozenge compositions Patheon Softgels, Inc. (High Point, NC)   See Pricing
Reslizumab   See Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   See Pricing
Reslizumab   See Pricing Stabilizing alkylglycoside compositions and methods thereof Aegis Therapeutics LLC (San Diego, CA)   See Pricing
Reslizumab   See Pricing Stabilizing alkylglycoside compositions and methods thereof Aegis Therapeutics, LLC (San Diego, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Reslizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Reslizumab Australia 2014287067 2033-07-12   See Pricing
Reslizumab Australia 2014306597 2033-07-12   See Pricing
Reslizumab Australia 2014306683 2033-07-12   See Pricing
Reslizumab Australia 2017276231 2033-07-12   See Pricing
Reslizumab Canada 2918035 2033-07-12   See Pricing
Reslizumab Canada 2921378 2033-07-12   See Pricing
Reslizumab Canada 2921381 2033-07-12   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Dow
Mallinckrodt
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.